Phase III Trial of Benralizumab in Hypereosinophilic Syndrome

A multicentre, randomised, double-blind, placebo-controlled study will evaluate benralizumab versus placebo over a 24-week period, with an open-label extension for eligible HES patients. AstraZeneca is assessing efficacy and safety where endpoints include the time to first HES flare.